Published in J Exp Med on August 01, 1973
Comparative study of in vitro and in vivo drug effects on cell-mediated cytotoxicity. Immunology (1976) 2.76
Interaction of cholera toxin and toxin derivatives with lymphocytes. I. Binding properties and interference with lectin-induced cellular stimulation. J Exp Med (1974) 2.42
Differences in Cyclic AMP Changes after Stimulation by Prostaglandins and Isoproterenol in Lymphocyte Subpopulations. J Clin Invest (1975) 1.73
The generation and regulation of lymphocyte populations: evidence from differentiative induction systems in vitro. J Exp Med (1978) 1.48
Sympathetic modulation of immunity: relevance to disease. Cell Immunol (2008) 1.33
Fibroblast heterogeneity and prostaglandin regulation of subpopulations. Proc Natl Acad Sci U S A (1977) 1.27
Cholera toxin mimics melanocyte stimulating hormone in inducing differentiation in melanoma cells. Proc Natl Acad Sci U S A (1974) 1.15
Mechanisms responsible for defective human T-lymphocyte sheep erythrocyte rosette function associated with hepatitis B virus infections. J Clin Invest (1976) 1.13
Emergence of insulin receptors upon alloimmune T cells in the rat. J Clin Invest (1977) 1.09
Cholinergic augmentation of lymphocyte-mediated cytotoxicity. A study of the cholinergic receptor of cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1974) 1.07
Modulation of the random migration of human platelets. J Clin Invest (1974) 1.05
Psychoneuroimmunology: stress effects on pathogenesis and immunity during infection. Clin Microbiol Rev (1994) 1.05
Nicotinic acetylcholine receptor: evidence for a functionally distinct receptor on human lymphocytes. Proc Natl Acad Sci U S A (1979) 0.99
Neuroendocrine regulation of inflammation. Semin Immunol (2014) 0.95
Complement-dependent, polymorphonuclear neutrophil-mediated cytotoxicity of herpesvirus-infected cells: possible mechanism(s) of cytotoxicity. Immunology (1980) 0.90
The modulation by prostaglandins of increases in lymphocyte traffic induced by bradykinin. Immunology (1984) 0.86
Stimulation of monocyte cGMP by leukocyte dialysates. An antigen-independent property of dialyzable transfer factor. J Clin Invest (1975) 0.86
Cyclic AMP reduces and cyclic GMP increases the traffic of lymphocytes through peripheral lymph nodes of sheep in vivo. Immunology (1982) 0.86
Tissue T and B cell infiltration of primary and metastatic cancer. J Clin Invest (1976) 0.85
Increased adenosine triphosphatase in leukocytes of asthmatic children. J Clin Invest (1974) 0.81
Response of lymphocyte guanyl cyclase to propranolol, noradrenaline, thymoxamine, and acetylcholine in extrinsic bronchial asthma. Br Med J (1975) 0.81
Viral infection-homograft interactions in a murine model. J Clin Invest (1978) 0.81
Enhancement of "one-way" human mixed lymphocyte reaction by cholinergic agents. Clin Exp Immunol (1976) 0.79
Impaired antibody responses in alloxan diabetic mice. Clin Exp Immunol (1977) 0.78
Bad news and good news: the present status and future prospects of human kidney transplantation. Trans Am Clin Climatol Assoc (1976) 0.77
2006 Homer W. Smith Lecture: taming T cells. J Am Soc Nephrol (2007) 0.77
Intercellular immunological controls and modulation of cyclic AMP levels. Some doubts. Immunology (1976) 0.77
Electrophysiology of T lymphocyte cholinergic receptors. Proc Natl Acad Sci U S A (1980) 0.76
Treatment of autoimmune MRL/Mp-lpr/lpr mice with cholera toxin. Clin Exp Immunol (1987) 0.75
Ionophore-A23187-induced cellular cytotoxicity: a cell fragment mediated process. Immunology (1980) 0.75
A protein binding assay for adenosine 3':5'-cyclic monophosphate. Proc Natl Acad Sci U S A (1970) 23.79
Adenosine 3',5'-phosphate in biological materials. I. Purification and properties of cyclic 3',5'-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3',5'-phosphate in human urine. J Biol Chem (1962) 12.79
Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology (1968) 11.20
Immunoglobulin determinants on the surface of mouse lymphoid cells. Nature (1970) 8.35
Cytotoxic effects of lymphoid cells in vitro. Adv Immunol (1969) 8.18
Specific in vitro cytotoxicity of thymus-derived lymphocytes sensitized to alloantigens. Nature (1970) 4.84
The role of cyclic 3',5' adenosine monophosphate in the specific cytolytic activity of lymphocytes. J Immunol (1972) 3.51
Elevation of guanosine 3',5'-cyclic phosphate in rat heart after perfusion with acetylcholine. Proc Natl Acad Sci U S A (1970) 3.48
Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. J Exp Med (1972) 3.31
Cells mediating specific in vitro cytotoxicity. II. Probable autonomy of thymus-processed lymphocytes (T cells) for the killing of allogeneic target cells. J Exp Med (1972) 3.00
Cyclic nucleotide-dependent protein kinases. X. An assay method for the measurement of quanosine 3',5'-monophosphate in various biological materials and a study of agents regulating its levels in heart and brain. J Biol Chem (1972) 2.35
Rejection of ascites tumor allografts. I. Isolation, characterization, and in vitro reactivity of peritoneal lymphoid effector cells from BALB-c mice immune to EL4 leukosis. J Exp Med (1972) 2.13
Alteration of the cytotoxic action of sensitized lymphocytes by cholinergic agents and activators of adenylate cyclase. Proc Natl Acad Sci U S A (1972) 2.01
Effects of cholera toxin on in vitro models of immediate and delayed hypersensitivity. Further evidence for the role of cyclic adenosine 3',5'-monophosphate. J Clin Invest (1973) 1.94
The role of cyclic AMP in the cytolytic activity of lymphocytes. J Immunol (1971) 1.78
Biologic properties of rat antibodies. I. Antigen-binding by four classes of anti-DNP antibodies. J Immunol (1968) 1.50
Stimulation of adenosine 3',5'-monophosphate hydrolysis by guanosine 3',5'-monophosphate. J Biol Chem (1971) 1.41
Elevation of cyclic guanosine 3',5'-monophosphate levels in dog thyroid slices caused by acetylcholine and sodium fluoride. J Biol Chem (1972) 1.22
Immunoglobulins of rat colostrum. J Immunol (1970) 1.15
Regulatory role of the cyclic nucleotides in alloimmune lymphocyte mediated cytotoxicity. Effect of imidazole. Transplant Proc (1973) 0.83
Cold urticaria: release into the circulation of histamine and eosinophil chemotactic factor of anaphylaxis during cold challenge. N Engl J Med (1976) 17.77
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med (2000) 11.90
Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science (2000) 9.92
Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A (1976) 6.65
Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol (1982) 5.44
C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b. J Immunol (1971) 5.41
Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc Natl Acad Sci U S A (1977) 5.23
Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res (2001) 4.87
Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3). J Immunol (1973) 4.78
Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med (1975) 4.69
C3 inactivator of man. I. Hemolytic measurement by the inactivation of cell-bound C3. J Immunol (1969) 4.38
A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med (1971) 4.07
Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med (1990) 4.06
Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity (1997) 4.05
Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med (1985) 4.00
A prealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein. J Exp Med (1972) 3.93
Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. J Exp Med (1973) 3.83
A neutrophil-immobilizing factor derived from human leukocytes. I. Generation and partial characterization. J Exp Med (1972) 3.75
Uncertainty in xenotransplantation: individual benefit versus collective risk. Nat Med (1998) 3.54
The IgE-mediated release of an eosinophil leukocyte chemotactic factor from human lung. J Immunol (1971) 3.51
Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol (1979) 3.50
Five years' experience in renal transplantation with immunosuppressive drugs: survival, function, complications, and the role of lymphocyte depletion by thoracic duct fistula. Ann Surg (1968) 3.34
Renal transplantation. N Engl J Med (1994) 3.33
Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. J Exp Med (1972) 3.31
Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci U S A (1983) 3.30
The biologically active leukotrienes. Biosynthesis, metabolism, receptors, functions, and pharmacology. J Clin Invest (1984) 3.26
The stoichiometric measurement of the serum inhibition of the first component of complement by the inhibition of immune hemolysis. J Immunol (1968) 3.24
B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity (1997) 3.22
Properdin factor D: characterization of its active site and isolation of the precursor form. J Exp Med (1974) 3.21
A stoichiometric assay for the fourth component of complement in whole human serum using EAC'la-gp and functionally pure human second component. J Immunol (1967) 3.18
Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. J Invest Dermatol (1983) 3.18
Slow reacting substances of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources. Proc Natl Acad Sci U S A (1980) 3.18
Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med (1999) 3.17
The complement system of man. I. N Engl J Med (1972) 3.09
Antibodies involved in antigen-induced release of slow reacting substance of anaphylaxis (SRS-A) in the guinea pig and rat. J Exp Med (1967) 3.08
A pre-albumin activator of prekallikrein. J Immunol (1970) 2.95
Simultaneous flow cytometric analysis of human T cell activation antigen expression and DNA content. J Exp Med (1983) 2.94
Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci U S A (1980) 2.94
Stimulation of human neutrophil leukocyte aerobic glucose metabolism by purified chemotactic factors. J Clin Invest (1974) 2.90
Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. J Exp Med (1977) 2.87
Interleukin 3: A differentiation and growth factor for the mouse mast cell that contains chondroitin sulfate E proteoglycan. J Immunol (1984) 2.85
Native heparin from rat peritoneal mast cells. J Biol Chem (1977) 2.79
Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med (1999) 2.74
Inactivation of slow reacting substance of anaphylaxis by human eosinophil arylsulfatase. J Immunol (1975) 2.73
Immunologic rejection of human cancer transplanted with a renal allograft. N Engl J Med (1968) 2.70
Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts. J Exp Med (1987) 2.69
Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J Immunol (1982) 2.69
Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. J Immunol (1986) 2.68
An eosinophil leukocyte chemotactic factor of anaphylaxis. J Exp Med (1971) 2.65
C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol (1976) 2.64
Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant (2007) 2.61
Purification and synthesis of eosinophilotactic tetrapeptides of human lung tissue: identification as eosinophil chemotactic factor of anaphylaxis. Proc Natl Acad Sci U S A (1975) 2.56
Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. II. Influence of cellular levels of cyclic AMP. Fed Proc (1972) 2.55
The complement system in rheumatoid synovitis. I. An analysis of complement component activities in rheumatoid synovial fluids. Arthritis Rheum (1971) 2.53
Identification of the C(6)-S-conjugate of leukotriene A with cysteine as a naturally occurring slow reacting substance of anaphylaxis (SRS-A). Importance of the 11-cis-geometry for biological activity. Biochem Biophys Res Commun (1980) 2.49
CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med (1995) 2.48
Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci (1992) 2.47
Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med (1970) 2.43
Mediation of local homeostasis and inflammation by leukotrienes and other mast cell-dependent compounds. Nature (1981) 2.41
Immunological release of histamine and slow-reacting substance of anaphylaxis from human lung. I. Modulation by agents influencing cellular levels of cyclic 3',5'-adenosine monophosphate. J Exp Med (1971) 2.39
Tryptase from human pulmonary mast cells. Purification and characterization. J Biol Chem (1981) 2.37
The physicochemical characteristics and purification of slow-reacting substance of anaphylaxis. J Immunol (1973) 2.34
Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation. N Engl J Med (1972) 2.33
Hereditary deficiency of the second component of complement (C'2) in man. J Clin Invest (1966) 2.32
The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator. J Exp Med (1972) 2.31
Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor. J Immunol (1986) 2.31
IL-15 and IL-2: a matter of life and death for T cells in vivo. Nat Med (2001) 2.29
Tumor-associated eosinophilotactic factor. N Engl J Med (1974) 2.27
Cloned human interferon-gamma, but not interferon-beta or -alpha, induces expression of HLA-DR determinants by fetal monocytes and myeloid leukemic cell lines. J Immunol (1984) 2.26
Slow reacting substance of anaphylaxis. Adv Immunol (1969) 2.23
Properdin: initiation of alternative complement pathway. Proc Natl Acad Sci U S A (1975) 2.20
Inactivation of slow reacting substance of anaphylaxins (SRS-A) by arylsulfatases. J Immunol (1974) 2.19
Properdin factor D. II. Activation to D by properdin. J Exp Med (1974) 2.19
Hereditary deficiency of the second component of complement (C2) in man: correlation of C2 haemolytic activity with immunochemical measurements of C2 protein. Immunology (1970) 2.17
Effects of intravenous administration of slow-reacting substance of anaphylaxis, histamine, bradykinin, and prostaglandin F2alpha on pulmonary mechanics in the guinea pig. J Clin Invest (1974) 2.16
Cyclic AMP, ATP, and reversed anaphylactic histamine release from rat mast cells. J Immunol (1974) 2.16
Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3. J Clin Invest (1988) 2.15
Intrarenal distribution of blood flow in the transplanted dog kidney: effect of denervation and rejection. J Clin Invest (1967) 2.14
The events of primary T cell activation can be staged by use of Sepharose-bound anti-T3 (64.1) monoclonal antibody and purified interleukin 1. J Immunol (1985) 2.14
Culture from mouse bone marrow of a subclass of mast cells possessing a distinct chondroitin sulfate proteoglycan with glycosaminoglycans rich in N-acetylgalactosamine-4,6-disulfate. J Biol Chem (1982) 2.13
Cytomegalovirus infection after renal allotransplantation. JAMA (1967) 2.08
Interaction of plasma kallikrein with the C1 inhibitor. J Immunol (1970) 2.07
Current concepts in immunology: the alternative pathway of complement--a system for host resistance to microbial infection. N Engl J Med (1980) 2.07
Leukotriene B4 action on endothelium mediates augmented neutrophil/endothelial adhesion. Proc Natl Acad Sci U S A (1984) 2.06
Megaloblastic hematopoiesis in uremia and in patients on long-term hemodialysis. N Engl J Med (1967) 2.06
Cyclosporine: a new immunosuppressive agent for organ transplantation. Ann Intern Med (1984) 2.03
Alteration of the cytotoxic action of sensitized lymphocytes by cholinergic agents and activators of adenylate cyclase. Proc Natl Acad Sci U S A (1972) 2.01
Immunologic release of beta-hexosaminidase and beta-glucuronidase from purified rat serosal mast cells. J Immunol (1979) 2.01
Coculture of interleukin 3-dependent mouse mast cells with fibroblasts results in a phenotypic change of the mast cells. Proc Natl Acad Sci U S A (1986) 2.00
A beta-glucan inhibitable receptor on human monocytes: its identity with the phagocytic receptor for particulate activators of the alternative complement pathway. J Immunol (1985) 2.00
Hereditary deficiency of the second component of complement (C'2) in man: further observations on a second kindred. J Immunol (1967) 1.98